Substantiating the concerns about recombinant human activated protein C use in sepsis.
Deans
Katherine J
KJ
Minneci
Peter C
PC
Banks
Steven M
SM
Natanson
Charles
C
Eichacker
Peter Q
PQ
D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D003422:Critical Care / Q000379:methods; D016638:Critical Illness; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D011379:Prognosis; D011486:Protein C / Q000009:adverse effects* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated